US Oncology picks up Cure magazine

Share this article:
US Oncology picks up Cure magazine
US Oncology picks up Cure magazine
US Oncology announced the purchase of Cure Media Group today, a move signaling an increased focus on cancer patients. US Oncology is a practice management and drug distribution firm.

Cure Media Group and its flagship magazine title, Cure, were previously owned by Medical Media Holdings, and has a print circulation of around 325,000. Around 176,000 of those issues go out to home subscribers, said Alexandra Hurd, PR and marketing specialist at Cure Media Group, with the rest going to oncology offices, infusion rooms, non-profits, hospitals and academic groups.

Editorial staff at Cure, including publisher Susan McClure and editor-at-large Kathy LaTour, will remain in place. Financial terms of the deal were not disclosed.  

Circulation numbers will go up under US Oncology's stewardship, as the free magazine goes out to all US Oncology-affiliated practices, and over 720,000 cancer patients treated within that network, according to Hurd. “We had been looking for ways to increase distribution, especially to newly diagnosed patients and patients just entering [cancer] treatments,” she said. “It was the right time and the right place.”

US Oncology offers full-service practice management, as well as à la carte offerings to oncology practices, including prescription delivery and distribution, billing, payment and patient services. Cure magazine will go out to the company's affiliated physicians operating at 493 locations, which includes 98 radiation oncology facilities in 39 states, according to a US Oncology release.

Hurd says the majority of Cure's advertisers are pharmaceutical companies, with a smattering of ads from insurance providers and clinics. Cure magazine is located on the web at

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...